Dave Singh

48PUBLICATIONS
115CO-AUTHORS
Haematological tumoursMolecular targetsDecision makingCharacterisation of biological macromoleculesAllergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (48)

|Sep 01, 2026
A first-in-human study of CAL101, a monoclonal antibody targeting S100A4.

|Aug 07, 2026
Identifying molecular signatures underpinning treatment responses to novel therapeutics influencing COVID-19 outcomes.

|Jun 12, 2026
Defining disease stability in chronic obstructive pulmonary disease: evidence from phase 3 clinical trials.

|Mar 18, 2026
Early clinical pharmacology evaluation of the novel anti-inflammatory macrolide, glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions.

Dave Singh, Kate Hanrott, Olof Breuer

|Dec 24, 2025
Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32-Week Randomized Phase 1b Multiple Ascending-Dose Trial.

Dave Singh, Chaim M Brickman, Peter Lloyd

|Oct 29, 2025
The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma.

Seblewongel Asrat, Wei Keat Lim, Subhashini Srivatsan

Pageof 8

Frequent Collaborators

6 joint publications

David M G Halpin

4 joint publications

MeiLan K Han

3 joint publications

Alberto Papi

3 joint publications

Peter Daley-Yates